biotech / news / / Reuters
Yes, absolutely," GSK's Hesham Abdullah said on the call.
GSK's Mo-rez showed a 62% tumor shrinkage rate in platinum-resistant ovarian cancer patients.
KEY POINTS
- Mo-rez achieved a 67% tumor shrinkage rate in endometrial cancer patients in early trials.
- GSK plans to initiate three additional Mo-rez studies in the coming months.
- Mo-rez targets the B7H4 protein, which is present on gynecological cancer cells but rare in healthy tissue.
- The antibody-drug conjugate market is projected to reach $31 billion by 2030.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →